Newswire (Published: Wednesday, August 14, 2019, Received: Wednesday, August 14, 2019, 5:24:18 PM CDT)
Word Count: 538
2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting out of Tampa, United States, by NewsRx editors, research stated, “Most prostate cancer in African American men lacks the ETS (E26 transforming specific) family fusion event (ETS-). We aimed to establish clinically relevant biomarkers in African American men by studying ETS dependent gene expression patterns to identified race specific genes predictive of outcomes.”
Funders for this research include Prostate Cancer Foundation, American Cancer Society, V Foundation, NCI Comprehensive Cancer Center.
Our news journalists obtained a quote from the research from H. Lee Moffitt Cancer Center and Research Institute, “Two multicenter cohorts of a total of 1,427 men were used for the discovery and validation (635 and 792 men, respectively) of race specific predictive biomarkers. We used false discovery rate adjusted q values to identify race and ETS dependent genes which were differentially expressed in African American men who experienced biochemical recurrence within 5 years. Principal component modeling along with survival analysis was done to assess the accuracy of the gene panel in predicting recurrence. We identified 3,047 genes which were differentially expressed based on ETS status. Of these genes 362 were differentially expressed in a race specific manner (false discovery rate 0.025 or less). A total of 81 genes were race specific and over expressed in African American men who experienced biochemical recurrence. The final gene panel included APOD, BCL6, EMP1, MYADM, SRGN and TIMP3. These genes were associated with 5-year biochemical recurrence (HR 1.97, 95% CI 1.27-3.06, p = 0.002) and they improved the predictive accuracy of clinicopathological variables only in African American men (60-month time dependent AUC 0.72). In an effort to elucidate biological features associated with prostate cancer aggressiveness in African American men we identified ETS dependent biomarkers predicting early onset biochemical recurrence only in African American men.”
According to the news editors, the research concluded: “Thus, these ETS dependent biomarkers representing ideal candidates for biomarkers of aggressive disease in this patient population.”
For more information on this research see: African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. The Journal of Urology, 2019;202(2):247-255. The Journal of Urology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.
Our news journalists report that additional information may be obtained by contacting K. Yamoah, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States. Additional authors for this research include M.I. Echevarria, S. Awasthi, C.H. Cheng, A.E. Berglund, R.J. Rounbehler, T.A. Gerke, J.L. Cleveland, J.Y. Park, M. Takhar, E. Davicioni, E.A. Klein, S.J. Freedland, A.E. Ross, E.M. Schaeffer, R.B. Den and W. Rayford.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1097/JU.0000000000000193. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
American Cancer Society Inc.
H. Lee Moffitt Cancer Center and Research Institute Inc.
Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices